2015

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

Pankaj Oberoi
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
http://digitalcommons.wustl.edu/open_access_pubs/4551

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research


Abstract

The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer’s disease (AD). Blood-based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebrospinal fluid biomarker approaches. Despite the fact that preanalytical processing is the largest source of variability in laboratory testing, there are no currently available standardized preanalytical guidelines. The current international working group provides the initial starting point for such guidelines for...
standardized operating procedures (SOPs). It is anticipated that these guidelines will be updated as additional research findings become available. The statement provides (1) a synopsis of selected preanalytical methods utilized in many international AD cohort studies, (2) initial draft guidelines/SOPs for preanalytical methods, and (3) a list of required methodological information and protocols to be made available for publications in the field to foster cross-validation across cohorts and laboratories.

© 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Keywords: Biomarkers; Blood; Serum; Plasma; Alzheimer’s disease; Dementia; Diagnosis; Treatment

1. Introduction

There is a large concern regarding the lack of reproducibility of research findings across independent laboratories, within laboratory settings, and particularly from academic laboratory settings to industry settings [1–4]. In fact, an “unspoken rule” among venture capital firms is that 50% of published studies will not replicate in industrial labs [4] and the National Institutes of Health (NIH) recently outlined a plan to address this problem [2]. While there are a large number of factors contributing to this issue, one key factor is the substantial variability in study designs, definitions, outcomes, and analytic models that make replication less likely [1]. While in the discovery phase of science, it is important to have substantial flexibility; however, as scientific discovery proceeds closer to the clinic, there is an increased need for optimization and standardization if these discoveries are to replicate reliably and pass regulatory authority. Unfortunately, there is oftentimes a disconnect between academic and industrial laboratories that hampers the movement of important scientific discovery to clinical practice, and the generation of standardized methods is one way to bridge this gap. The purpose of this white paper is the generation of the first set of guidelines for use in research of blood-based biomarkers of Alzheimer’s disease (AD).

A major impediment to the therapeutic development and clinical trial design for AD is the lack of a sensitive, easily-obtained biomarker of disease [5–7]. Biomarkers of disease presence, subtypes (i.e., endophenotypes), treatment response, and progression are needed to advance therapeutic and preventative opportunities for this rapidly growing health care crisis [5, 8–13]. Biomarkers are also considered promising tools to enhance all phases of drug discovery and development programs by allowing the validation of mechanisms of action [14]. They can be employed in clinical trials to improve diagnostic accuracy in trial participants, thus allowing cohorts of patients to be enriched with cases of AD (patient enrichment) [15,16]. In light of this, such markers may not only be useful in patient identification, selection, and stratification into clinical trials, but may also be useful in the identification of novel therapeutic targets.

Over the last two decades, the search for biomarkers that have diagnostic and prognostic utility in AD has grown exponentially [6,11] with most work focusing on neuroimaging and cerebrospinal (CSF) methodologies [6,11,17]. Advanced neuroimaging and CSF techniques yield highly accurate diagnostic accuracy within the clinic-based settings for detecting AD and blood-based biomarkers represent an approach for enhancing the utility of imaging and CSF-based modalities by serving as a generalized screening tool. In fact, it has been proposed that blood-based methods can serve as the first step in a multistep diagnostic process [7] as is the case with many other pathologies, such as cardiovascular diseases, infectious diseases, and cancer. All screen positives could be referred for neuroimaging or CSF assessment for confirmatory purposes (e.g. for diagnostics or enrollment into clinical trials).

There has been a significant increase in research efforts examining the potential for blood-based biomarkers of AD. While the search was largely unsuccessful for decades, recent work shows promise. In a seminal study, Ray and colleagues [18] analyzed 120 plasma-based proteins and developed an algorithm consisting of an 18-biomarker panel that accurately

---

1 Additional members of the Blood-Based Biomarker Interest Group (BBBIG) and Standards for Alzheimer’s Research in Blood biomarkers (STAR-B) include Howard M. Fillit, Alzheimer’s Drug Discovery Foundation, New York, NY, USA; Lisa J. Bain, Elverson, PA, USA; David Wholley and Judy Siuciak, The Biomarkers Consortium, Foundation for the National Institutes of Health, USA; David Holtzman, Department of Neurology, Washington University, School of Medicine, St. Louis, MO, USA; Gary Kong, Edith Cowan University, Australia; Andrew Saykin, Indiana University, Center for Neuroimaging, IN, USA; Robert Nagele, University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine, NJ, USA; Dwight German, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA; Diane Stephenson, Critical Path Institute, USA; Andrew Watt, Alzheimer’s Australia Dementia Research Foundation, Australia; Howard Schullman, Captron Proteomics, USA; Pedro Pesini, Aracelon Biotech S.L., Spain; Tony Phelps, National Institutes of Aging, USA; Steve Younkin, Mayo Clinic, Jacksonville, FL, USA; Thomas Kodadek, Departments of Chemistry & Cancer Biology, The Scripps Research Institute, Scripps Florida, Jupiter, FL, USA; Morten Karstad, Nordic Bioscience Biomarkers and Research, Neurodegenerative Diseases, Herlev, Denmark; Anders Lonneborg and Magnus Sjogren, DiaGenic ASA, Oslo, Norway; William Hu, Department of Neurology, Center for Neurodegenerative Disease Research, Emory University School of Medicine, Atlanta, USA; Tony Wyss-Coray, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA; Joyce Suh, SynarcImaging, San Francisco, CA, USA; Dan Perry, Alliance for Aging Research, Washington, DC, USA; Rachel L. Nosheny, La Jolla, CA, and Stanford, CA, USA; Hugo Vanderstichele, AD x Neurosciences, Gent, Belgium; Steven Warring, Marshfield Clinic; Donald Royal, University of Texas Health Science Center–San Antonio, TX, USA; George Perry, University of Texas San Antonio, TX, USA.
distinguished AD patients from healthy controls with an overall classification accuracy of 89% and accurately identified 81% of mild cognitive impairment (MCI) patients who progressed to AD within a 2- to 6-year follow-up period [18]. This study represented the first major support for the notion that an AD biomarker profile could yield excellent accuracy; however, enthusiasm waned when the findings did not cross-validate on an independent assay platform [19]. Despite this initial setback, other groups have continued to identify promising signals in peripheral blood, suggesting that a blood-based AD screen may be on the horizon [20–29]. Recently, data from well-characterized international cohorts have yielded additional candidate biomarkers and panels [25,30]. In the Texas Alzheimer’s Research and Care Consortium (TARCC) cohort a serum-based algorithm yielded a 30-protein profile with a sensitivity of 88% and specificity of 82% for clinical AD diagnosis [31]. The biomarker panel from baseline plasma collected in the Australia Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) study consisted of 18 analytes that could distinguish AD from healthy controls with a sensitivity of 85% and specificity of 93% [29]. A 17-biomarker panel was associated with the diagnosis of MCI and AD in independent cohorts from the University of Pennsylvania and Washington University in St. Louis, and two of these analytes were found to be highly correlated with the CSF t-tau/amyloid-beta (Aβ) 42 ratio [30], a strong predictor of future cognitive decline [32,33]. There have been several markers consistently altered in AD across cohorts. As outlined by Kiddle and colleagues [34], an example of these markers (and number of cohorts they have been replicated across) include: apolipoprotein E (APOE) (five cohorts), alpha-2-macroglobulin (five cohorts), complement C3 (five cohorts), pancreatic prohormone (five cohorts), serum amyloid P (four cohorts), tumor necrosis factor (two cohorts), and serum albumin (four cohorts). Many of these blood-based studies are similar in terms of utilizing a common analytical platform; however, the biomarker panels obtained are strikingly different, sharing only a few common analytes. For example, in the study by Hu and colleagues, several markers were significantly related to dementia status but in the opposite direction across cohorts despite the use of the same analytic platform. Additionally, several studies have examined the Alzheimer’s Disease Neuroimaging Initiative (ADNI) proteomic database with different protein signatures reported [29–31]. The discrepant findings may be due to the approach employed as the ADNI cohort was utilized as the validation sample with the protein signatures being developed in other cohorts (i.e. University of Pennsylvania, Washington University, AIBL, TARCC). For comprehensive recent reviews of AD proteomic studies conducted across a broad range of cohorts see Lista and colleagues [35] and Kiddle and colleagues [34].

Apart from the fact that different initial panels were tested (along with different study design), inconsistencies across study findings could be attributable to many preanalytical variables, both technical and biological, across studies which may have significant impact on the outcomes of the proteomic analyses. There are numerous possible sources of preanalytical variations or errors across studies [36]; however, out of these, we have attempted to highlight only a few important ones. For example, the selection of study participants in terms of their ethnicity, lifestyle parameters, and statistically sufficient numbers could be an important source of variation. In addition, within-subject variation has long been highlighted as a possible source of concern as participants need to adhere to certain guidelines during the course of the study [37]. Variations could also be introduced by work staff in terms of sample collection mode, collection tubes, preparation, transportation, handling, storage and processing, and different calibration protocols of the equipment being used [37,38]. One of the most important factors is the fraction of the blood used for testing (serum vs. plasma) as not only the abundance of a particular analyte may vary in these different fractions, but additives such as heparin, citrate, or ethylenediaminetetraacetic acid (EDTA) influence the required processing methods and their presence may impact biomarker stability and detectability [39–41]. Table 1 presents a list of some of the uncontrollable and controllable variables that can impact findings from studies of blood-based biomarkers in AD. The uncontrollable variables should be reported in the methods of protocols and taken into account statistically, whereas the controllable variables represent scientific areas where harmonization can occur.

A key step toward generating consistency across studies with regards to blood-based biomarkers is the establishment of guidelines for preanalytical protocols [5,42–45] mirroring the ongoing initiatives for CSF AD biomarkers [17,46,47]. In fact, such standardization efforts for blood-based biomarkers have been underway in other fields for some time [24,48–52] and the European Federation of Clinical Chemistry and Laboratory Medicine (available at http://efcclm.eu/) working group reported a substantial reduction in analytic error with improvements in standardization and reliability of instruments, reagents, and techniques [53]. Notably, the STANDARDS for Alzheimer’s Research in Blood biomarkers

| Table 1 | Controllable and uncontrollable variables that can impact blood-biomarker findings within Alzheimer’s disease (AD) studies |
|---------|__________________________________________________________________________|
| **Controlable variables** | **Uncontrollable variables** |
| Time of collection | Demographic characteristics (age, sex, ethnicity, or race) |
| Fasting status | APOE ε4 (and other genes) |
| Needle size and location of draw | Smoking status |
| Handling of tubes (e.g. inversions) | Gestation |
| Tube type and additives | Diet |
| Tube collection order | Medications |
| Time of sample in collection tube | Non-AD comorbidities |
| Centrifugation parameters | Alcohol use |
| Time from collection to freeze | Activity level |
| Temperature of freeze | |
| Freeze-thaw cycles | |
| Aliquot size | |

Abbreviation: APOE, apolipoprotein E
(STAR-B) was born of this need and combined with the Blood-Based Biomarker Interest Group (BBBIG) to create a Professional Interest Area (PIA) of the Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART; available at https://act.alz.org/site/SPageServer?pagename=ISTAART_homepage). The ultimate goal of this international working group is the advancement of blood-based biomarkers for the improvement of diagnosis, treatment, and care for those suffering from AD. This international collaboration recently has provided an overview regarding the status of the field [5] and the Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation recently and jointly convened a workshop to discuss the state of the field [54]. The current work from the working group was undertaken to (1) summarize selected methods across many ongoing longitudinal cohorts, (2) take an initial step toward the provision of guidelines for preanalytical methods for studies examining the development and role of blood-based biomarkers of AD, and (3) provide a minimum set of preanalytical variables that must be provided in publications (within the publication or as a supplement) in this line of work. Moreover, a set of next-step variables specific to the elderly and dementia populations to be examined has been proposed as areas for further research is needed on this topic to inform the next revision of the current guidelines.

2. Ongoing studies

Protocols from 10 (ongoing) AD cohort studies, collaborations, and the National Institute on Aging (NIA) Best Practice Guidelines (also currently being updated) were reviewed. These studies were selected as they (1) denote ongoing longitudinal studies with specific foci (including blood-based) in biomarkers of AD, (2) represent a significant portion of the investigators and/or publications in the topic area, and (3) were willing to share detailed protocols regarding blood collection and processing. These studies also presented established procedures for requesting biological samples. Those studies or groups who did not respond to either the request for protocols or for whom did not provide confidential methods were subsequently excluded. The studies included consisted of the following: the Alzheimer’s Center Amsterdam [55], Alzheimer’s Disease Cooperative Study (ADCS) [56], Alzheimer’s Disease Neuroimaging Initiative [57], Australian Imaging, Biomarkers and Lifestyle study [58,59], Dominantly Inherited Alzheimer Network (DIAN) [60–62], Health and Aging Brain among Latino Elders (HABLE) [63], King’s Dementia Studies [64], NIA Best Practices [65], TARCC [25,26,31,66], and the Washington University Adult Children Study (ACS) [67,68].

As reported in Table 1, there is significant consistency, but also inconsistency and lack of technical details across existing studies. The TARCC, ADCS, NIA Best Practices, and Alzheimer Center Amsterdam studies do not require fasting blood draws, whereas all others make use of them. On the other hand, while “overnight fast” was needed for several studies, only the DIAN protocol provided a definition for fasting duration (i.e. 8 hours). Many studies provided information regarding needle gauge to be used, but not all, with 21-gauge being the most commonly utilized size. Tube type varied across studies, with little consistency across the category of serum tube selected. Lavender/purple top EDTA plasma (K2) was commonly utilized for plasma collection. Centrifugation speed varied across studies by speed, duration, temperature and number of spins, with little consistency noted. Additionally, the number of revolutions per minute (rpm) in some studies but g-force in others was utilized for documentation of centrifugation speed. Sample preparation time (total) was most commonly less than or equal to two hours. Samples were most commonly stored immediately at −80°C, but some studies used immediate freeze on dry ice before placement in −80°C or liquid nitrogen. The most common long-term storage condition was −80°C.

3. Guidelines for preanalytical methods

There is a sizable literature documenting the impact of preanalytical methods on proteomic results, with most of the errors in laboratory testing coming from outside the analytical phase [37] and the majority originating from the preanalytical processing phase [69–72]. Specifically, the role of preanalytical variables—affecting the quality of the utilized samples and, consequently, the quality of the data produced—is frequently disregarded in clinical proteomic analyses [73]. In this regard, it has been suggested that 46% of the errors in laboratory testing comes from the preanalytical phase [74].

If any blood-based AD biomarkers are to move from research only (discovery phase or cross-validation phase) to in vitro diagnostic use, standardization of methodologies is compulsorily required. While there is still a great need for additional discovery in the area of blood-based biomarkers, there is also the necessity to “lock-down” or further clinically validate the potential utility of the putative markers currently available, which is the focus of the current guidelines. In the United States, all testing on human samples as clinical diagnostics must be performed within a regulated good laboratory practice setting as defined by the Clinical Laboratory Improvement Amendment of 1988 and other associated regulatory guidelines [37]. Many procedures for reaching clinical diagnostic status are determined by standard protocols, standard operating procedures and national or international standards, which include the preanalytical procedures provided by the Clinical Laboratory Standards Institute (CLSI, available at http://clsi.org/) (formally the National Committee for Clinical Laboratory Standards), with strict adherence to such standards being important [37].

3.1. Preblood draw

There are a number of patient/participant-related factors that will impact blood marker results that cannot be
accounted for unless proper documentation is obtained. Some physiological variables to consider include demographics (age, sex, race/ethnicity), overall health, food and beverages consumed before collection, chronic drugs/alcohol use, dietary supplements, smoking, gestation, diet, exercise, posture or bed rest, and patient medical conditions and medication status [37,45,48,50,52]. Attempts should be made to record information related to these variables as much as possible for appropriate adjustments to be made during the analysis of results [37,48]. As can be seen from Table 2, most ongoing studies use fasting blood-collection although the definition of fasting (i.e., 6, 8, 12 hours) is not articulated, despite the fact that fasting duration has a known impact on many blood-based biomarker levels. Prior work also suggests that some, but not all, blood biomarkers exhibit diurnal fluctuations [75–77], which can have a substantial impact on the clinical significance of such markers [78]. Standardizing to a morning (before 10 AM fasting) blood draw would address the possible diurnal fluctuation issues by harmonizing sample collection times across studies.

3.2. Blood collection

There are a number of variables associated with the blood collection procedure itself that can impact laboratory assay results. Needle gauge, single-, or multidraw needles, and needle composition can impact assay results [37], with hemolysis being a major consideration [79–82]. For example, in an emergency department setting, the use of a 22-gauge needle was significantly associated with an increased risk of hemolysis [83]. Based on prior results, a 21-gauge needle is preferred [82,84,85]. Needles can be composed of various materials including stainless steel, aluminum, titanium, chromium, iron, manganese, nickel, and alloys which may impact assays that measure various metals within the blood. A detailed description of how to perform a venipuncture is provided by CLSI document H3-A6. There are advantages and disadvantages for both serum and plasma, which can fluctuate based on the specific marker of interest (e.g., see Rai and Vitzthum [37]).

The site used for blood withdrawal is also an important aspect to consider [86]. The median cubital vein, usually easily found and accessed, is considered the preferred site. The preparation of the blood collection sites necessitates an accurate cleaning of the skin with alcohol (2-propanol) that should be allowed to evaporate, given that the contamination of blood with residual alcohol may induce hemolysis, increase the concentrations of some analytes, therefore, producing interferences [87]. In addition, the position of the patient (standing, lying, and sitting) can have an impact on the hematocrit, and, thus, may cause fluctuations in the levels of the analytes [88].

Moreover, the collection tube can significantly have an affect the obtained results [37,82]. In fact, tube components of rubber stoppers, tube wall materials, surfactants, anticoagulants, separator gels, clot activators, anticoagulants can all impact assay results [82]. To comply with Occupational Safety and Health Administration (available at https://www.osha.gov/) guidelines to minimize risks from shattering tubes, plastic tubes have replaced glass collection tubes [82,89]. Although plastic tubes offer many advantages, such as increased gas and water permeability, they also offer several disadvantages such as the adhesion of proteins to tube walls [82], which has been an issue identified for CSF AD biomarkers [90–93]. A detailed review of the impact of tube components on blood-based assay performance has been published by Bowen 2010 [82]. The order of tube collection in blood draw is also important (CLSI H3-A6 and Rai and Vitzthum [37]) and the current recommendations can be found in Fig. 1.

3.3. Blood processing

CLSI H18-A4 provides detailed information regarding procedures for handling and processing blood specimens for laboratory tests. The time considerations from blood-draw to storage, storage temperature, centrifugation parameters, storage volume and container type are all important for sample processing [37,44,79,94,95]. A key point for consideration is the separation of the sample from the tubes immediately after centrifugation. Although the processing time may vary by study and the importance by protein being measured, one should not store aliquots from serum/plasma that have been in contact with cells for more than two hours [79]. Review of Table 1 shows that most ongoing protocols require the total processing time to be 2 hours or less, which is preferable. See H18-A4 for a detailed list of uncentrifuged specimen stability for a range of times and sample types. Per H18-A4, centrifugation parameters that should not be subject to variation are: horizontal rotors should be utilized and first centrifugation speed should be at 2000g for 10 min [50]. Parameters that are subject to variation but should be documented include: (1) presence and type of separator, (2) temperature of centrifugation, and (3) number of centrifugations (single or double). With regards to postcentrifugation processing, the parameters that should not be subject to variation include: (1) serum/plasma is not to be heated or otherwise inactivated, and (2) no storage at −20 °C. Parameters subject to variation but requiring documentation include: (1) type of secondary container (tube, straw), (2) time interval between centrifugation and freezing, (3) sample temperature before aliquoting and freezing, (4) storage temperature, (5) number of freeze/thaw cycles, and (6) duration of storage [50,79]. Polypropylene tips and tubes are recommended to reduce adherence of analytes to walls.

3.4. Storage

It has been well acknowledged that protein stability and enzymatic activity are strictly dependent on temperature
<table>
<thead>
<tr>
<th>Cohort</th>
<th>Fasting</th>
<th>Needle Size</th>
<th>Serum Sample Type</th>
<th>Plasma Sample Type</th>
<th>Centrifuge Speed/Time</th>
<th>Processing time</th>
<th>Storage method (immediate)</th>
<th>Storage method (long-term)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TARCC [25,26,31,66]</td>
<td>No</td>
<td>ND</td>
<td>Serum-separating tubes (tiger tops)</td>
<td>BD EDTA tubes (purple top)</td>
<td>1300 × g/10 min; room temperature</td>
<td>2 h; sample processing started within 1 h of draw</td>
<td>Frozen on wet ice if unable to be frozen immediately; placed in −20°C freezer</td>
<td>−80°C</td>
</tr>
<tr>
<td>ADNI [57]</td>
<td>Yes</td>
<td>21G</td>
<td>(plain red tops)</td>
<td>EDTA tubes</td>
<td>3000 rpm/15 min</td>
<td>2 h; sample processing started within 1 h following blood draw</td>
<td>Frozen on dry ice for 20 minutes then shipped same day; on arrival samples are thawed, realiquoted and placed in −80°C freezer</td>
<td>−80°C</td>
</tr>
<tr>
<td>AIBL [58,59]</td>
<td>Yes</td>
<td>21G</td>
<td>Sarstedt s-monovette serum-gel (brown top)</td>
<td>a) Sarstedt s-monovette lithium heparin (green top)</td>
<td>Serum: 1800 × g/15 minutes 20°C Plasma: step1: 200 g/10 min 20°C, step2: 800 g/15 min 20°C</td>
<td>Total processing must be completed within 3.5 h; blood processing must be started within 20 min of after blood draw</td>
<td>Frozen immediately at −80°C</td>
<td>Liquid nitrogen</td>
</tr>
<tr>
<td>ADCS [56]</td>
<td>ND</td>
<td>Ideal but not required</td>
<td>Small gauge needle</td>
<td>ND</td>
<td>EDTA tubes or heparin tubes</td>
<td>3000 rpm/10 min</td>
<td>ND</td>
<td>−80°C</td>
</tr>
<tr>
<td>NIA Best Practice Guidelines [65]</td>
<td>ND</td>
<td>Ideal but not required</td>
<td>Small gauge needle</td>
<td>ND</td>
<td>EDTA tubes or heparin tubes</td>
<td>3000 rpm/10 min</td>
<td>ND</td>
<td>−80°C</td>
</tr>
<tr>
<td>HABLE [63]</td>
<td>Yes</td>
<td>21G</td>
<td>Serum-separating tubes (tiger tops)</td>
<td>BD EDTA tubes (purple top)</td>
<td>1300 × g/10 min; room temperature</td>
<td>2 h; sample processing started within 1 h of draw</td>
<td>Flash freeze on dry ice at site, shipped, stored at −80°C, thawed, aliquot, re-flash frozen on dry ice and stored at −80°C</td>
<td>−80°C</td>
</tr>
<tr>
<td>DIAN [60,61]</td>
<td>Yes</td>
<td>21G butterfly</td>
<td>Red top plain tubes</td>
<td>EDTA tubes (lavender top)</td>
<td>2000 × g/15 min; room temperature</td>
<td>Process serum after allowing to sit at room temperature for 30 min</td>
<td>Liquid nitrogen (subset)</td>
<td>Liquid nitrogen (subset)</td>
</tr>
<tr>
<td>ACS [67,68]</td>
<td>Yes</td>
<td>21G butterfly</td>
<td>N/A</td>
<td>EDTA tubes</td>
<td>2000 × g/15 min 4°C</td>
<td>Within 1–2 h of collection</td>
<td>Receive samples on wet ice, aliquot, placed in −80°C freezer/liquid nitrogen</td>
<td>−84°C</td>
</tr>
<tr>
<td>King’s Dementia Studies [64]</td>
<td>Yes</td>
<td>21G or 23G (depending on vein size)</td>
<td>Serum tube (gold top)</td>
<td>EDTA tubes (purple top)</td>
<td>3000 rpm/8 min</td>
<td>Time from blood draw to samples freezing kept within 2–3 h &lt;2 h, usually within 1 h,</td>
<td>−80°C</td>
<td>−80°C</td>
</tr>
<tr>
<td>Alzheimer Center Amsterdam [55]</td>
<td>No</td>
<td>21 G BD (also 22,23 G present)</td>
<td>BD serum gel tubes (red top)</td>
<td>BD EDTA tubes (purple top)</td>
<td>1800 g/10 min 40°C</td>
<td>Immediately frozen at −80°C</td>
<td>−80°C</td>
<td>−80°C</td>
</tr>
</tbody>
</table>

Abbreviations: EDTA, ethylenediamine tetraacetic acid; ND, not documented in protocol.
Preanalytic Processing Guidelines

1. Fasting - The majority of Alzheimer’s studies globally utilizes fasting blood collection and thus is recommended (at least 8 hours since last meal). Whether fasting or non-fasting procedures are utilized, time since last meal should be documented.

2. Needle gauge -
   a. 21g needle is preferable
   b. Needle gauge can range from 19-23g

3. Order of blood draw should be as follows (skip tubes not being utilized):
   1. Blood Culture Tube
   2. Coagulation tube (blue top)
   3. Serum
      1. Serum separator (e.g. gold or red-grey “tiger top”)
      2. Serum without gel (e.g. red top)
   4. Heparin
      1. Heparin plasma (e.g. green top)
      2. Heparin plasma (e.g. gel separator – light green or green-grey top)
   5. EDTA with or without separator (e.g. lavender/purple or pearl top)
   6. Glycolytic inhibitor (e.g. gray top)
   7. PAXgene blood RNA tube

4. Processing –
   a. Total processing time <= 2hrs from “stick-to-freezer”.
   b. Serum/plasma should be physically separated from contact with cells as soon as possible (<2hrs). Do not store aliquots from serum/plasma that have been in contact with cells for >2hrs.
   c. Serum should be clotted in vertical position at room temperature before centrifugation (30-60m) if patient is not on anti-coagulant therapy.
   d. Plasma tube should be gently inverted 5-10 times.
   e. Relative centrifugal force (RCF; g-force) is preferred over revolutions per minute (rpm) in standard operating procedures (SOPs) and publications.
   f. First centrifugation at 2000g for 10min with horizontal rotors preferable.
   g. Aliquots should be made in polypropylene tubes (screw top preferably)(or straws) using polypropylene tips for pipets.

5. Storage –
   a. Long-term storage should be at -80°C or liquid nitrogen. If storage on dry ice is utilized for shipment, the headspace should be vented or the sample should be allowed to sit in -70°C or -80°C freezer for 9hrs prior to thaw.
   b. Small aliquots (generally not larger than 0.5 ml) are recommended for storage. Avoid unnecessary thawing and refreezing of samples and ensure consistent freeze thaw

Fig. 1. Preanalytic processing guidelines.

[96]. Long-term storage should be at −80°C or liquid nitrogen. According to Rai and colleagues [50], liquid nitrogen storage should represent an excellent system to ensure protein stability. However, this way is not often practicable in comparison with the availability of −80°C freezers. Hence, the long-term storage temperature should be set at −80°C, using freezers whose temperature oscillations are absent or extremely diminished. If storage on dry ice is utilized for shipment, the headspace should be vented or the sample should be allowed to sit in −70°C freezer for nine hours before thaw to facilitate protein stability [97]. Fig. 1 provides the proposed guidelines for preanalytical processing outlined here.

4. Minimum data required for publication

For attempts to be made at cross-validation of biomarker findings across cohorts and laboratories, a minimum amount of information is required in addition to utilizing common methods. The select preanalytical elements outlined above need to be made available to the scientific community within the manuscript or online supplement. Fig. 1 not only provides the current guidelines, but also a template for provision of key preanalytic elements to be provided within publications for use by other teams.

5. Elderly- and dementia-specific preanalytic processing variables requiring additional research

Although the current guidelines provide the first-step in the process toward the generation of standards for the field, there remain several topics that require additional research. Most importantly relates to the question of how these preanalytical methods require modification for geriatric populations. For example, the World Health Organization points
out skin breakdown as a potential complication of capillary sampling among elderly patients [98]. However, a systematic study of the impact of the proposed guidelines specifically among the elderly has not been undertaken. In fact, review of the previously published materials (including CLSI documents) does not provide information that is age specific. Therefore, it is recommended that the need for specific alterations in the guidelines for the target population be undertaken with the current guidelines as a starting framework.

6. Conclusions and future perspectives

For blood-based biomarker work in AD to progress, there is a need for the adoption of guidelines to standardize preanalytical methods across cohorts and laboratories [5,42]. Such guidelines will allow for validation or cross-validation across laboratories and cohorts to further validate the clinical performance of putative markers where signals have been established. The current guidelines are an attempt to verify such existing putative markers for specific clinical utilities and are not intended to stifle in any way new discoveries, which are certainly needed in the blood-based AD biomarker arena. The Blood Based Biomarkers (PIA) of ISTAART combined the efforts of the STAR-B and BBBIG working groups for a single cohesive effort. This working group recently published a position article on the future of blood-based biomarkers of AD in which several needed areas of work were outlined, which included the need for guidelines and standards for preanalytical methods [5]. The current project reflects the continued efforts of that working group and development of the first such international guidelines for preanalytical processing of bloods in AD research. It is anticipated that these guidelines will be updated as needed based on advancements of the field.

There are multiple potential clinical utilities for blood-based AD biomarkers, and the study design must be reflective of that particular purpose. For example, blood-based AD biomarkers of disease presence, amyloid positivity, CSF biomarker positive (i.e. diagnostic markers) may be developed within clinic settings of case-control designs; however, if such markers are to be clinically useful in primary care settings, they must be tested and evaluated within such settings as the diagnostic accuracy will vary greatly due to the difference in disease base rates and diagnostic practice [99–101]. To date, no such studies have been carried out validating putative blood-based AD biomarkers within primary care settings. Issues around analytical assay validation, discovery versus clinical diagnostic-grade platforms, etc. have also received little attention. As with preanalytical processing variables, CLSI guidelines are currently available for assessing performance of assays (e.g. EP5, EP6, EP7, EP10, EP14, EP15, EP17, ILA21, ILA23), which should be followed if the assay is to move toward clinical application.

To date, there are numerous signals for putative blood-based biomarkers and biomarker panels, although no consensus has been reached so far following Institute of Medicine (IOM) guidelines [102]. The purpose of the provision of the current guidelines from the international working
group is to begin the process and dialogue of moving toward standardized methods that can be utilized to move putative blood-based biomarkers closer to clinical or additional research practices. An important step will be the detailed disclosure of the preanalytic parameters used for collection of clinical samples in publications of the clinical evaluation of biomarkers. The current document provides information regarding the minimum necessary information regarding these preanalytic methods used to facilitate cross-validation of methods across research teams. Additional working group documents will address both analytic and postanalytic variables.

Acknowledgments

Sid E. O’Bryan has multiple patents pending, submitted by the University of North Texas Health Science Center wherein he is an inventor and receives research grants from the National Institutes of Health, National Institute on Aging, award number R01AG039389 and P30AG12300. Veer Gupta reports no conflicts of interests. Kim Henriksen’s research was supported by the Danish Research Foundation and reports no conflicts of interests. Melissa Edwards reports no conflicts of interests. Andreas Jeromin holds affiliations with Quanterix, Inc. and reports no conflict of interests. Chantal Bazenet reports no conflicts of interests. Holly Soares holds affiliations with Bristol-Myers Squibb and reports no conflicts of interests. Simon Lovestone reports no conflicts of interests. Harald Hampel is supported by the AXA Research Fund, the Fondation Université Pierre et Marie Curie, and the Fondation pour la Recherche sur Alzheimer, Paris, France. The research leading to these results has received funding from the program “Investissements d’avenir” ANR-10-IAIHU-06. Thomas Montine receives funding from the National Institutes of Health, award Number P50AG05136 and reports no conflict of interest. Kaj Blennow has research supported by the Swedish Research Council, grant #14002, and has served on Advisory Boards for Innogenetics, Belgium. Tatiana Foroud reports no conflict of interest. Maria Carrillo reports no conflict of interest. Neill Graff-Radford reports no conflict of interest. Christoph Laske reports no conflict of interest. Monique Breteler reports no conflict of interest. Leslie Shaw reports no conflict of interest. John Q. Trojanowski may accrue revenue in the future on patents submitted by the University of Pennsylvania wherein he is co-Inventor and received revenue from the sale of Avid to Eli Lily as co-inventor on imaging related patents submitted by the University of Pennsylvania. Nicole Schupf reports no conflicts of interests. Robert A. Riessman reports no conflicts of interest. Anne M. Fagan reports no conflicts of interests. Pankaj Oberoi and Robert Umek hold affiliations with Meso Scale Discovery and report no conflicts of interests. Michael W. Weiner reports no conflicts of interests. Paula Grammas reports no conflicts of interests. Melissa Edwards reports no conflicts of interests. Ralph Martins reports no conflicts of interests.


